Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi, India.
Immunopharmacol Immunotoxicol. 2010 Jun;32(2):348-56. doi: 10.3109/08923970903300151.
Combination therapy with intravesical bacillus Calmette-Guerin (BCG) plus interferon-alpha2b (IFN-alpha2b) for superficial transitional cell carcinoma (TCC) seems to be immune-dependent and activation of Th1 immune response is required for clinical efficacy. The present study evaluates circulating serum cytokine profiles (Th1/Th2 cytokines IFN-gamma, IL-2 TNF-alpha, IL-4, IL-6 and IL-10) in 41 bladder cancer patients prior to transurethral resection of tumor (TURBT) (pre-therapy), and following intravesical combination immunotherapy (post-therapy) and their association with recurrence. Mean levels of IL-2 and TNF-alpha were significantly reduced while IL-4, IL-6 and IL-10 were significantly enhanced in pre-therapy samples as compared to controls. Mean levels of IFN-gamma, IL-2 and TNF-alpha were significantly increased while IL-4 and IL-10 were significantly reduced in patients after instillation of combination immunotherapy. These findings suggest that bladder cancer patients develop Th2 dominant status with deficient type 1 immune response that shows tendency to reversal following therapy.
联合膀胱内卡介苗（BCG）和干扰素-α2b（IFN-α2b）治疗浅表性移行细胞癌（TCC）似乎是免疫依赖性的，需要激活 Th1 免疫反应才能发挥临床疗效。本研究评估了 41 例膀胱癌患者在经尿道肿瘤切除术（TURBT）（治疗前）、膀胱内联合免疫治疗（治疗后）前后的循环血清细胞因子谱（Th1/Th2 细胞因子 IFN-γ、IL-2、TNF-α、IL-4、IL-6 和 IL-10），并分析其与复发的关系。与对照组相比，治疗前样本中 IL-2 和 TNF-α的平均水平显著降低，而 IL-4、IL-6 和 IL-10 的平均水平显著升高。在灌注联合免疫治疗后，IFN-γ、IL-2 和 TNF-α的平均水平显著升高，而 IL-4 和 IL-10 的平均水平显著降低。这些发现表明，膀胱癌患者表现出 Th2 优势状态，伴有 1 型免疫反应缺陷，治疗后有逆转趋势。
